ReviewJournal of clinical medicine2020
Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections.
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed.
- Long-term protection from naturally acquired immunity against hepatitis E virus reinfection.Nature communications · 2025Trial
- Hepatitis E Virus Infection in Pregnant Women.Microorganisms · 2026Review
- Extra-Hepatic Manifestations of Hepatitis E Virus (HEV): A Narrative Review on Meningoencephalitis.Life (Basel, Switzerland) · 2026Review
- Host-interferon-stimulated gene response to virus-host recombinant variants of hepatitis E virus and enhanced viral replication.Microbiology spectrum · 2026Article
- Seroprevalence and Risk Factors for Hepatitis E Virus in a Metropolis of Northeastern Brazil: A Population-Based Survey.Zoonoses and public health · 2026Article
- Hepatitis E virus and renal injury: A review of pathogenesis, pathology, and clinical management.Infectious medicine · 2026Review
- Natural Alkaloids Against Liver Injury: Mechanistic Insights and Multi-Target Therapeutic Potential.Biomolecules · 2026Review
- A One Health Approach to Hepatitis E Virus in Venezuela: Low Seroprevalence in Humans and First Genomic Evidence of Hepatitis E Virus Genotype 3 in a Domestic Swine.Microorganisms · 2026Article
- Current global estimates, risk factors, and knowledge gaps for Hepatitis E virus (HEV): A scoping review.PLoS neglected tropical diseases · 2026Article
- Hepatitis A to E in People with HIV: A Virus-Specific Review of Prevention and Treatment.Infectious diseases and therapy · 2026Review
- Proliferative Cell Targeting and Epithelial Cell Turnover Fuels Hepatitis E Virus Replication in Human Intestinal Enteroids.Gastro hep advances · 2026Article
- Article
- The Gut Microbiota in Elderly Patients with Acute Hepatitis E Infection.Journal of clinical and translational hepatology · 2025Article
- Validation of an Optimised Method for Quantitative Detection of Hepatitis E Virus in Pork Sausage.Food and environmental virology · 2025Article
- Plasmacytoid dendritic cell sensing of hepatitis E virus is shaped by both viral and host factors.Life science alliance · 2025Article
- Trends and Challenges in the Detection and Environmental Surveillance of the Hepatitis E Virus.Microorganisms · 2025Review
- Zoonotic infections in semi-domesticated eurasian tundra reindeer (Rangifer tarandus tarandus) in Fennoscandia - a review.One health outlook · 2025Review
- Effectiveness of Cold Smoking on Inactivating Murine Norovirus in Salami-Like Pork Sausages (Mettwurst), and Hepatitis E Virus and Murine Norovirus in Solution.Food and environmental virology · 2025Article
- A patient with acute hepatitis E and intractable vomiting: a case report.Frontiers in medicine · 2025Article
- Cost-Effectiveness Analysis of Hepatitis E Vaccination Strategies for Swine Workers.Transboundary and emerging diseases · 2025Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis throughout the world. Most infections are acute but they can become chronic in immunocompromised patients, such as solid organ transplant patients, patients with hematologic malignancy undergoing chemotherapy and those with a human immunodeficiency virus (HIV) infection. Extra-hepatic manifestations, especially neurological and renal diseases, have also been described. To date, four main genotypes of HEV (HEV1-4) were described. HEV1 and HEV2 only infect humans, while HEV3 and HEV4 can infect both humans and animals, like pigs, wild boar, deer and rabbits. The real epidemiology of HEV has been underestimated because most infections are asymptomatic. This review focuses on the recent advances in our understanding of the pathophysiology of acute HEV infections, including severe hepatitis in patients with pre-existing liver disease and pregnant women. It also examines the mechanisms leading to chronic infection in immunocompromised patients and extra-hepatic manifestations. Acute infections are usually self-limiting and do not require antiviral treatment. Conversely, a chronic HEV infection can be cleared by decreasing the dose of immunosuppressive drugs or by treating with ribavirin for 3 months. Nevertheless, new drugs are needed for those cases in which ribavirin treatment fails.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.